Spots Global Cancer Trial Database for nemtabrutinib
Every month we try and update this database with for nemtabrutinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005) | NCT05347225 | Hematological M... | Nemtabrutinib | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) | NCT06136559 | Chronic Lymphoc... Small Lymphocyt... | Nemtabrutinib Ibrutinib Acalabrutinib | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | NCT03162536 | Lymphoma, B-Cel... Small Lymphocyt... Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Diffuse Large B... Richter's Trans... Follicular Lymp... Marginal Zone L... | Nemtabrutinib | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) | NCT05458297 | Chronic Lymphoc... Mantle Cell Lym... Follicular Lymp... Richter Transfo... | Zilovertamab ve... Nemtabrutinib | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005) | NCT05347225 | Hematological M... | Nemtabrutinib | 18 Years - | Merck Sharp & Dohme LLC | |
| Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) | NCT04728893 | Hematologic Mal... Waldenstroms Ma... Non-Hodgkins Ly... Chronic Lymphoc... | Nemtabrutinib | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | NCT03162536 | Lymphoma, B-Cel... Small Lymphocyt... Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Diffuse Large B... Richter's Trans... Follicular Lymp... Marginal Zone L... | Nemtabrutinib | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) | NCT05458297 | Chronic Lymphoc... Mantle Cell Lym... Follicular Lymp... Richter Transfo... | Zilovertamab ve... Nemtabrutinib | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) | NCT05624554 | Chronic Lymphoc... Small Lymphocyt... | Nemtabrutinib Fludarabine Cyclophosphamid... Bendamustine Rituximab Truxima Ruxience Riabni | 18 Years - | Merck Sharp & Dohme LLC | |
| A Clinical Study of Nemtabrutinib in Japanese Participants With Hematological Malignancies (MK-1026-002) | NCT05673460 | Mature B-cell N... | Nemtabrutinib | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) | NCT06136559 | Chronic Lymphoc... Small Lymphocyt... | Nemtabrutinib Ibrutinib Acalabrutinib | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010) | NCT05947851 | Leukemia, Lymph... Leukemia, Chron... Small-Cell Lymp... Lymphoma, Small... CLL SLL | Nemtabrutinib Venetoclax Rituximab | 18 Years - | Merck Sharp & Dohme LLC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
